Status:
COMPLETED
Prophylactic Enoxaparin Dosing in Roux-en-Y Gastric Bypass Surgery Patients at St. Vincent Carmel
Lead Sponsor:
Ascension St. Vincent Carmel Hospital
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess anti-factor Xa concentrations in patients given prophylactic enoxaparin after bariatric surgery.
Detailed Description
FDA-approved enoxaparin dosing for venous thromboembolism (VTE) prophylaxis is a fixed-dose regimen irrespective of body mass index (BMI) or actual body weight (ABW). Clinical trials suggest that dosi...
Eligibility Criteria
Inclusion
- Patients 18 years and older undergoing primary roux-en-Y gastric bypass surgery at St. Vincent Carmel Bariatric Center of Excellence
Exclusion
- Receiving anticoagulation therapy prior to surgery (i.e. warfarin)
- Did not receive enoxaparin after surgery
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01230658
Start Date
January 1 2010
End Date
July 1 2011
Last Update
August 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Vincent Carmel Bariatric Center of Excellence
Carmel, Indiana, United States, 46032